Minocycline-an old drug for a new century: emphasis on methicillin-resistant Staphylococcus aureus (MRSA) and Acinetobacter baumannii

International Journal of Antimicrobial Agents

Volumn 34, Issue 5, 2009, Pages 395-401

  Bishburg, Eliahu ^a   Bishburg, Kathryn ^b  

^a NEWARK BETH ISRAEL MEDICAL CENTER   (United States)

^b Middlesex Regulatory Consulting   (United States)

Author keywords

Acinetobacter infection; Intravenous; Minocycline; MRSA

Indexed keywords

AMIKACIN; BACTERIAL PROTEIN; CARRIER PROTEIN; COLISTIN; DAPTOMYCIN; DOXYCYCLINE; IMIPENEM; LEVOFLOXACIN; LINEZOLID; METICILLIN; MINOCYCLINE; OUTER MEMBRANE PROTEIN C; OUTER MEMBRANE PROTEIN F; OXYTETRACYCLINE; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN B; RIFAMPICIN; SULTAMICILLIN; TETRACYCLINE; TIGECYCLINE; VANCOMYCIN;

ACINETOBACTER BAUMANNII; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; AUTOIMMUNE HEPATITIS; BACTERIAL ENDOCARDITIS; BACTERIOSTASIS; BRAIN PSEUDOTUMOR; CANDIDIASIS; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL PRACTICE; COMMUNICABLE DISEASE; DISEASE SEVERITY; DIZZINESS; DRUG ABSORPTION; DRUG BILE LEVEL; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG LIVER LEVEL; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME INACTIVATION; GASTROINTESTINAL DISEASE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HOSPITAL INFECTION; HUMAN; IN VITRO STUDY; LIVER DYSFUNCTION; LIVER FAILURE; LOADING DRUG DOSE; LUPUS LIKE SYNDROME; MAXIMUM PLASMA CONCENTRATION; MEDLINE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MORBIDITY; MORTALITY; NAUSEA AND VOMITING; NONHUMAN; OSTEOMYELITIS; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; SINGLE DRUG DOSE; SKIN DISEASE; SKIN INFECTION; TINNITUS; UNITED STATES; VASCULITIS; VENTILATOR ASSOCIATED PNEUMONIA; VERTIGO; VESTIBULAR DISORDER;

EID: 69949183988     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2009.06.021     Document Type: Note

References (82)

1. Arias C.A., and Murray B.E. Antibiotic-resistant bugs in the 21st century-a clinical super-challenge. N Engl J Med 360 (2009) 439-443
2. National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004;32:470-85.
3. Biedenbach D.J., Moet G.J., and Jones R.N. Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002). Diagn Microbiol Infect Dis 50 (2004) 59-69
4. Rennie R.P., Jones R.N., and Mutnick A.H. Occurrence and antimicrobial susceptibility patterns of pathogens isolated from skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 2000). Diagn Microbiol Infect Dis 45 (2003) 287-293
5. Cosgrove S.E., Qi Y., Kaye K.S., Harbarth S., Karchmer A.W., and Carmeli Y. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect Control Hosp Epidemiol 26 (2005) 166-174
6. Karageorgopoulos D.E., and Falagas M.E. Current control and treatment of multidrug-resistant Acinetobacter baumannii infections. Lancet Infect Dis 8 (2008) 751-762
7. Talbot G.H., Bradley J., Edwards Jr. J.E., Gilbert D., Scheld M., and Bartlett J.G. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis 42 (2006) 657-668
8. Jonas M., and Cunha B.A. Minocycline. Ther Drug Monit 4 (1982) 137-145
9. Smilack J.D. The tetracyclines. Mayo Clin Proc 74 (1999) 727-729
10. Chopra I., Hawkey P.M., and Hinton M. Tetracyclines, molecular and clinical aspects. J Antimicrob Chemother 29 (1992) 245-277
11. Nikaido H., and Thanassi D.G. Penetration of lipophilic agents with multiple protonation sites into bacterial cells: tetracyclines and fluoroquinolones as examples. Antimicrob Agents Chemother 37 (1993) 1393-1399
12. Oehler R., Polacek N., Steiner G., and Barta A. Interaction of tetracycline with RNA: photoincorporation into ribosomal RNA of Escherichia coli. Nucleic Acids Res 25 (1997) 1219-1224
13. Schnappinger D., and Hillen W. Tetracyclines: antibiotic action, uptake, and resistance mechanisms. Arch Microbiol 165 (1996) 359-369
14. Noah J.W., Dolan M.A., Babin P., and Wollenzien P. Effects of tetracycline and spectinomycin on the tertiary structure of ribosomal RNA in the Escherichia coli 30 S ribosomal subunit. J Biol Chem 274 (1999) 16576-16581
15. Chopra I., and Roberts M. Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev 65 (2001) 232-260
16. Paulsen I.T., Brown M.H., and Skurray R.A. Proton-dependent multidrug efflux systems. Microbiol Rev 60 (1996) 575-608
17. Roberts M.C. Tetracycline resistance in Peptostreptococcus species. Antimicrob Agents Chemother 35 (1991) 1682-1684
18. Testa R.T., Petersen P.J., Jacobus N.V., Sum P.E., Lee V.J., and Tally F.P. In vitro and in vivo antibacterial activities of the glycylcyclines, a new class of semisynthetic tetracyclines. Antimicrob Agents Chemother 37 (1993) 2270-2277
19. Spahn C.M., Blaha G., Agrawal R.K., Penczek P., Grassucci R.A., Trieber C.A., et al. Localization of the ribosomal protection protein Tet(O) on the ribosome and the mechanism of tetracycline resistance. Mol Cell 7 (2001) 1037-1045
20. Taylor D.E., and Chau A. Tetracycline resistance mediated by ribosomal protection. Antimicrob Agents Chemother 40 (1996) 1-5
21. Speer B.S., Bedzyk L., and Salyers A.A. Evidence that a novel tetracycline resistance gene found on two Bacteroides transposons encodes an NADP-requiring oxidoreductase. J Bacteriol 173 (1991) 176-183
22. Levy S.B., FitzGerald G.B., and Macone A.B. Changes in intestinal flora of farm personnel after introduction of a tetracycline-supplemented feed on a farm. N Engl J Med 295 (1976) 583-588
23. Zarantonelli L., Borthagaray G., Lee E.H., and Shafer W.M. Decreased azithromycin susceptibility of Neisseria gonorrhoeae due to mtrR mutations. Antimicrob Agents Chemother 43 (1999) 2468-2472
24. Barry A.L., Jones R.N., and Gavan T.L. Evaluation of the micro-media system for quantitative antimicrobial drug susceptibility testing: a collaborative study. Antimicrob Agents Chemother 13 (1978) 61-69
25. Draghi D.C., Tench S., Dowzicky M.J., and Sahm D.F. Baseline in vitro activity of tigecycline among key bacterial pathogens exhibiting multidrug resistance. Chemotherapy 54 (2008) 91-100
26. Bouchillon S.K., Hoban D.J., Johnson B.M., Johnson J.L., Hsiung A., and Dowzicky M.J. In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004). Diagn Microbiol Infect Dis 52 (2005) 173-179
27. Hoban D.J., Bouchillon S.K., Johnson B.M., Johnson J.L., and Dowzicky M.J. In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004). Diagn Microbiol Infect Dis 52 (2005) 215-227
28. Souli M., Kontopidou F.V., Koratzanis E., Antoniadou A., Giannitsioti E., Evangelopoulou P., et al. In vitro activity of tigecycline against multiple-drug-resistant, including pan-resistant, Gram-negative and Gram-positive clinical isolates from Greek hospitals. Antimicrob Agents Chemother 50 (2006) 3166-3169
29. Waites K.B., Duffy L.B., and Dowzicky M.J. Antimicrobial susceptibility among pathogens collected from hospitalized patients in the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial. Antimicrob Agents Chemother 50 (2006) 3479-3484
30. Dijkshoorn L., Nemec A., and Seifert H. An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii. Nat Rev Microbiol 5 (2007) 939-951
31. Halstead D.C., Abid J., and Dowzicky M.J. Antimicrobial susceptibility among Acinetobacter calcoaceticus-baumannii complex and Enterobacteriaceae collected as part of the Tigecycline Evaluation and Surveillance Trial. J Infect 55 (2007) 49-57
32. Coelho J.M., Turton J.F., Kaufmann M.E., Glover J., Woodford N., Warner M., et al. Occurrence of carbapenem-resistant Acinetobacter baumannii clones at multiple hospitals in London and Southeast England. J Clin Microbiol 44 (2006) 3623-3627
33. Hawley J.S., Murray C.K., Griffith M.E., McElmeel M.L., Fulcher L.C., Hospenthal D.R., et al. Susceptibility of Acinetobacter strains isolated from deployed U.S. military personnel. Antimicrob Agents Chemother 51 (2007) 376-378
34. Tan T.Y., Ng L.S., Tan E., and Huang G. In vitro effect of minocycline and colistin combinations on imipenem-resistant Acinetobacter baumannii clinical isolates. J Antimicrob Chemother 60 (2007) 421-423
35. Saivin S., and Houin G. Clinical pharmacokinetics of doxycycline and minocycline. Clin Pharmacokinet 15 (1988) 355-366
36. Smith C., Woods C.G., and Woods M.J. Absorption of minocycline. J Antimicrob Chemother 13 (1984) 93
37. Agwuh K.N., and MacGowan A. Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. J Antimicrob Chemother 58 (2006) 256-265
38. Watanabe A., Anzai Y., Niitsuma K., Saito M., Yanase K., and Nakamura M. Penetration of minocycline hydrochloride into lung tissue and sputum. Chemotherapy 47 (2001) 1-9
39. Carney S., Butcher R.A., Dawborn J.K., and Pattison G. Minocycline excretion and distribution in relation to renal function in man. Clin Exp Pharmacol Physiol 1 (1974) 299-308
40. Macdonald H., Kelly R.G., Allen E.S., Noble J.F., and Kanegis L.A. Pharmacokinetic studies on minocycline in man. Clin Pharmacol Ther 14 (1973) 852-861
41. Cartwright A.C., Hatfield H.L., Yeadon A., and London E. A comparison of the bioavailability of minocycline capsules and film-coated tablets. J Antimicrob Chemother 1 (1975) 317-322
42. Brogan T.D., Neale L., Ryley H.C., Davies B.H., and Charles J. The secretion of minocycline in sputum during therapy of bronchopulmonary infection in chronic chest diseases. J Antimicrob Chemother 3 (1977) 247-251
43. Welling P.G., Shaw W.R., Uman S.J., Tse F.L., and Craig W.A. Pharmacokinetics of minocycline in renal failure. Antimicrob Agents Chemother 8 (1975) 532-537
44. Yin L.Y., Lazzarini L., Li F., Stevens C.M., and Calhoun J.H. Comparative evaluation of tigecycline and vancomycin, with and without rifampicin, in the treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis in a rabbit model. J Antimicrob Chemother 55 (2005) 995-1002
45. Craig W.A. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 26 (1998) 1-10
46. Bowker K.E., Noel A.R., and Macgowan A.P. Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 52 (2008) 4370-4373
47. Ruhe J.J., and Menon A. Tetracyclines as an oral treatment option for patients with community onset skin and soft tissue infections caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 51 (2007) 3298-3303
48. Goulden V., Glass D., and Cunliffe W.J. Safety of long-term high-dose minocycline in the treatment of acne. Br J Dermatol 134 (1996) 693-695
49. Garner S.E., Eady E.A., Popescu C., Newton J., and Li W.A. Minocycline for acne vulgaris: efficacy and safety. Cochrane Database Syst Rev (2003) CD002086
50. Smith K., and Leyden J.J. Safety of doxycycline and minocycline: a systematic review. Clin Ther 27 (2005) 1329-1342
51. Freeman K. Therapeutic focus. Minocycline in the treatment of acne. Br J Clin Pract 43 (1989) 112-115
52. Allen J.C. Minocycline. Ann Intern Med 85 (1976) 482-487
53. Williams D.N., Laughlin L.W., and Lee Y.H. Minocycline: possible vestibular side-effects. Lancet 2 (1974) 744-746
54. Meynadier J., and Alirezai M. Systemic antibiotics for acne. Dermatology 196 (1998) 135-139
55. Elkayam O., Yaron M., and Caspi D. Minocycline-induced autoimmune syndromes: an overview. Semin Arthritis Rheum 28 (1999) 392-397
56. Klein N.C., and Cunha B.A. New uses of older antibiotics. Med Clin North Am 85 (2001) 125-132
57. Barnes E.V., 2nd, Dooley D.P., Hepburn M.J., and Baum S.E. Outcomes of community-acquired, methicillin-resistant Staphylococcus aureus, soft tissue infections treated with antibiotics other than vancomycin. Mil Med 171 (2006) 504-507
58. Ruhe J.J., Monson T., Bradsher R.W., and Menon A. Use of long-acting tetracyclines for methicillin-resistant Staphylococcus aureus infections: case series and review of the literature. Clin Infect Dis 40 (2005) 1429-1434
59. Minuth J.N., Holmes T.M., and Musher D.M. Activity of tetracycline, doxycycline, and minocycline against methicillin-susceptible and -resistant staphylococci. Antimicrob Agents Chemother 6 (1974) 411-414
60. Lawlor M.T., Sullivan M.C., Levitz R.E., Quintiliani R., and Nightingale C. Treatment of prosthetic valve endocarditis due to methicillin-resistant Staphylococcus aureus with minocycline. J Infect Dis 161 (1990) 812-814
61. Yuk J.H., Dignani M.C., Harris R.L., Bradshaw M.W., and Williams Jr. T.W. Minocycline as an alternative antistaphylococcal agent. Rev Infect Dis 13 (1991) 1023-1024
62. Nicolau D.P., Freeman C.D., Nightingale C.H., Coe C.J., and Quintiliani R. Minocycline versus vancomycin for treatment of experimental endocarditis caused by oxacillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 38 (1994) 1515-1518
63. Raad I., Hanna H., Jiang Y., Dvorak T., Reitzel R., Chaiban G., et al. Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillin-resistant Staphylococcus bacteremic isolates embedded in biofilm. Antimicrob Agents Chemother 51 (2007) 1656-1660
64. Peleg A.Y., Potoski B.A., Rea R., Adams J., Sethi J., Capitano B., et al. Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report. J Antimicrob Chemother 59 (2007) 128-131
65. Griffith M.E., Yun H.C., Horvath L.L., and Murray C.K. Minocycline therapy for traumatic wound infections caused by the multidrug-resistant Acinetobacter baumannii-calcoaceticus complex. Infect Dis Clin Pract 16 (2008) 16-19
66. Wood G.C., Hanes S.D., Boucher B.A., Croce M.A., and Fabian T.C. Tetracyclines for treating multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia. Intensive Care Med 29 (2003) 2072-2076
67. Klevens M.R., Morrison M.A., Nadle J., Petit S., Gershman K., Ray S., et al., Active Bacterial Core Surveillance (ABCs) MRSA Investigators. Invasive methicillin resistant Staphylococcus aureus infections in the United States. JAMA 298 (2007) 1763-1771
68. Boyce J.M., Jackson M.M., Pugliese G., Batt M.D., Fleming D., Garner J.S., et al. Methicillin-resistant Staphylococcus aureus (MRSA): a briefing for acute care hospitals and nursing facilities. The AHA Technical Panel on Infections Within Hospitals. Infect Control Hosp Epidemiol 15 (1994) 105-115
69. Naimi T.S., LeDell K.H., Como-Sabetti K., Borchardt S.M., Boxrud D.J., Etienne J., et al. Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 290 (2003) 2976-2984
70. Gillet Y., Issartel B., Vanhems P., Fournet J.C., Lina G., Bes M., et al. Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet 359 (2002) 753-759
71. Maree C.L., Daum R.S., Boyle-Vavra S., Matayoshi K., and Miller L.G. Community-associated methicillin-resistant Staphylococcus aureus isolates causing healthcare-associated infections. Emerg Infect Dis 13 (2007) 236-242
72. Fournier P.E., and Richet H. The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin Infect Dis 42 (2006) 692-699
73. Munoz-Price L.S., and Weinstein R.A. Acinetobacter infection. N Engl J Med 358 (2008) 1271-1281
74. Falagas M.E., Bliziotis I.A., and Siempos I.I. Attributable mortality of Acinetobacter baumannii infections in critically ill patients: a systematic review of matched cohort and case-control studies. Crit Care 10 (2006) R48
75. Metan G., Alp E., Aygen B., and Sumerkan B. Acinetobacter baumannii meningitis in post-neurosurgical patients: clinical outcome and impact of carbapenem resistance. J Antimicrob Chemother 60 (2007) 197-199
76. Bergogne-Berezin E., and Towner K.J. Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin Microbiol Rev 9 (1996) 148-165
77. Jerassy Z., Yinnon A.M., Mazouz-Cohen S., Benenson S., Schlesinger Y., Rudensky B., et al. Prospective hospital-wide studies of 505 patients with nosocomial bacteraemia in 1997 and 2002. J Hosp Infect 62 (2006) 230-236
78. Murray C.K. Epidemiology of infections associated with combat-related injuries in Iraq and Afghanistan. J Trauma 64 3 Suppl. (2008) S232-S238
79. Jones R.N., Ferraro M.J., Reller L.B., Schreckenberger P.C., Swenson J.M., and Sader H.S. Multicenter studies of tigecycline disk diffusion susceptibility results for Acinetobacter spp. J Clin Microbiol 45 (2007) 227-230
80. Centers for Disease Control and Prevention (CDC). Acinetobacter baumannii infections among patients at military medical facilities treating injured U.S. service members, 2002-2004. MMWR Morb Mortal Wkly Rep 2004;53:1063-6.
81. Reinert R.R., Low D.E., Rossi F., Zhang X., Wattal C., and Dowzicky M.J. Antimicrobial susceptibility among organisms from the Asia/Pacific Rim, Europe and Latin and North America collected as part of TEST and the in vitro activity of tigecycline. J Antimicrob Chemother 60 (2007) 1018-1029
82. Ramirez J.A. Antibiotic streamlining: development and justification of an antibiotic streamlining program. Pharm Pract Manag Q 16 (1996) 19-34